Results 181 to 190 of about 53,817 (210)
Some of the next articles are maybe not open access.
Validity and Scope of ANVISA’s Prior Consent to the Patentability of Medical Inventions
GRUR International, 2022Penciclovirw
exaly +2 more sources
Anvisa's Prior Consent as a Contribution to Global Health and the One Health System
Advances in Data Mining and Database Management Book Series, 2022The participation of the National Health Surveillance Agency (ANVISA) in the granting of patents for pharmaceutical products and processes in Brazil took place since 2001, giving this sector of the Ministry of Health unprecedented legal competence, until then exclusive to the entity of the National Institute of Industrial Property (INPI).
Marilena C Villela Corrêa
exaly +2 more sources
Internal Standards (IS) Monitoring in CROs: Anvisa Perspective
Bioanalysis, 2019Gustavo Mendes, Lima Santos +1 more
exaly +3 more sources
PP30 The Fast Track In Drug Registration By ANVISA – Brazil And Possible Consequences
International Journal of Technology Assessment in Health Care, 2023IntroductionThe fast track in drug registration by the Brazilian Health Regulatory Agency, ANVISA, began in 2017 and is intended to prioritize analysis related to drugs relevant to public health. This process is appropriate in situations where there are no therapeutic alternative available or for technologies show significant improvement in safety ...
Silvana Kelles +12 more
openaire +1 more source
Access, Fairness and Affordability: Procedural Justice in NICE, Anvisa and Conitec
SSRN Electronic Journal, 2014Everywhere, health care systems are making hard choices about medicines. These choices are sensitive, controversial and often result in litigation. For example, the recent report in the UK about the drug Tamiflu casts doubt on the efficacy of the treatment and its value for money to the public health system.
Ricardo Perlingeiro, Christopher Newdick
openaire +1 more source
Should ANVISA be permitted to reject pharmaceutical patent applications in Brazil?
Expert Opinion on Therapeutic Patents, 2013Pharmaceutical manufacturers who seek new markets for expansion are particularly attracted to Brazil given its potential for growth and the expectation that it will be the fifth largest drug market by 2015. Given the significance of Brazil in the marketplace, strong patent protection for pharmaceutical products and processes is critical. In April 2013,
Lisa L, Mueller +1 more
openaire +2 more sources
ANVISA atualiza regras de pesquisa clínica
Brazilian Journal of PeriodontologyIsso mesmo, no último dia 2 de dezembro foram publicadas no Diário Oficial da União (DOU) a Resolução1 ANVISA (Agência Nacional de Vigilância Sanitária) nº 945 e a Instrução Normativa2 nº 338, ambas de 29 de novembro de 2024. Na área da Saúde, a busca pelas melhores práticas passa pela disponibilidade de estudos clínicos que assegurem eficácia e ...
openaire +1 more source
Anvisa intensifica controle de infecção em serviços de saúde
Revista De Saude Publica, 2004exaly +2 more sources